Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00511511
Status:
COMPLETED
Last Update Posted:
2010-01-05
First Post:
2007-08-03
Brief Title:
Angiogenesis Inhibitors and Hypertension Clinical Aspects
Sponsor:
Erasmus Medical Center
Organization:
Erasmus Medical Center
Study Overview
Official Title:
Angiogenesis Inhibitors and Hypertension Clinical Aspects
Status:
COMPLETED
Status Verified Date:
2009-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to find simple clinical and laboratory parameters to predict the development of hypertension and to elucidate the mechanism of hypertension during treatment with the tyrosine kinase inhibitor Sunitinib
Detailed Description:
Inhibition of angiogenesis with antibodies against vascular endothelial growth factor VEGF and VEGF receptor antagonists has become an established treatment for cancer An unanticipated side effect of angiogenesis inhibitors is the development of hypertension The pathogenesis of this hypertension is unknown Not all patients will develop hypertension However it is not known which patient will and which patient will not develop hypertension
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT-number 2007-002038-13 | None | None | None |